In HBV-associated HCC, CD4+ cytotoxic T cells are progressively reduced as HCC progresses, and a reduced number and/or functional impairment of CD4+ cytotoxic T cells correlates with poor clinical outcomes (98). This evidence concerns the gene CD4 and hepatocellular carcinoma.